Paradigm Biocapital Advisors LP Immatics N.V. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Immatics N.V. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 3,144,157 shares of IMTX stock, worth $18.3 Million. This represents 0.79% of its overall portfolio holdings.
Number of Shares
3,144,157
Previous 1,907,108
64.87%
Holding current value
$18.3 Million
Previous $8.6 Million
96.66%
% of portfolio
0.79%
Previous 0.44%
Shares
9 transactions
Others Institutions Holding IMTX
# of Institutions
74Shares Held
93.6MCall Options Held
158KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD18.3MShares$106 Million0.06% of portfolio
-
Suvretta Capital Management, LLC New York, NY12MShares$69.9 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY10.2MShares$59.1 Million0.55% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$54.5 Million2.22% of portfolio
-
Rtw Investments, LP New York, NY6.97MShares$40.5 Million0.58% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $443M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...